Relation Between Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Histopathologic Features and Review of the Literature

[1]  U. Wollina,et al.  Atypical fibroxanthoma: An analysis of 105 tumors , 2020, Dermatologic therapy.

[2]  A. Cesinaro,et al.  Atypical fibroxanthoma and pleomorphic dermal sarcoma: A reappraisal , 2020, Journal of cutaneous pathology.

[3]  D. Rhodes,et al.  A Genomic Survey of Sarcomas on Sun-Exposed Skin Reveals Distinctive Candidate Drivers and Potentially Targetable Mutations. , 2020, Human pathology.

[4]  M. Henderson,et al.  Management of pleomorphic dermal sarcoma , 2020, ANZ journal of surgery.

[5]  S. Paradela,et al.  Incidence rate and clinicopathological features of 62 atypical fibroxanthomas in a North‐Western Spanish population , 2020, The Australasian journal of dermatology.

[6]  A. De Leo,et al.  Could cathepsin-k be a driver of the myofibroblastic differentiation observed in dermatofibroma, atypical fibroxanthoma and pleomorphic dermal sarcoma? , 2019, Acta histochemica.

[7]  R. Novoa,et al.  Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Updates on Classification and Management. , 2019, Dermatologic clinics.

[8]  I. Petersen,et al.  Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype , 2019, Clinical Sarcoma Research.

[9]  S. Haferkamp,et al.  Expression of proton‐sensing G‐protein‐coupled receptors in selected skin tumors , 2018, Experimental dermatology.

[10]  T. Pfuhl,et al.  Expression of 3q oncogene SEC62 in atypical fibroxanthoma-immunohistochemical analysis of 41 cases and correlation with clinical, viral and histopathologic features , 2018, Oncology letters.

[11]  S. Arron,et al.  Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes , 2018, Journal of the American Academy of Dermatology.

[12]  A. Quaas,et al.  Immunohistochemical expression of melanocytic and myofibroblastic markers and their molecular correlation in atypical fibroxanthomas and pleomorphic dermal sarcomas , 2018, Journal of cutaneous pathology.

[13]  J. Utikal,et al.  MYC gene amplification is a rare event in atypical fibroxanthoma and pleomorphic dermal sarcoma , 2018, Oncotarget.

[14]  D. Schadendorf,et al.  Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles , 2018, Modern Pathology.

[15]  P. Fernández-Peñas,et al.  Atypical fibroxanthoma management: Recurrence, metastasis and disease‐specific death , 2018, The Australasian journal of dermatology.

[16]  D. Elder,et al.  WHO classification of skin tumours , 2018 .

[17]  J. Budczies,et al.  Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas , 2017, Oncotarget.

[18]  Teo Soleymani,et al.  Conception and Management of a Poorly Understood Spectrum of Dermatologic Neoplasms: Atypical Fibroxanthoma, Pleomorphic Dermal Sarcoma, and Undifferentiated Pleomorphic Sarcoma , 2017, Current Treatment Options in Oncology.

[19]  T. Mentzel,et al.  Atypical Fibroxanthoma Revisited. , 2017, Surgical pathology clinics.

[20]  I. Pastushenko,et al.  Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis. , 2016, Actas dermo-sifiliograficas.

[21]  A. Quaas,et al.  Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas , 2016, Oncotarget.

[22]  J. Tardío,et al.  Pleomorphic dermal sarcoma: a more aggressive neoplasm than previously estimated , 2016, Journal of cutaneous pathology.

[23]  Liurka V Lopez,et al.  Atypical Fibroxanthoma. , 2016, Archives of pathology & laboratory medicine.

[24]  S. Suster,et al.  Spindle Cell Atypical Fibroxanthoma: Myofibroblastic Differentiation Represents a Diagnostic Pitfall in This Variant of AFX , 2015, The American Journal of dermatopathology.

[25]  M. Tetzlaff,et al.  Metastatic Atypical Fibroxanthoma: A Series of 11 Cases Including With Minimal and No Subcutaneous Involvement , 2015, The American Journal of dermatopathology.

[26]  F. Toberer,et al.  Analysis of the lymphatic vessel architecture of atypical fibroxanthoma and pleomorphic dermal sarcoma. , 2014, Journal of the American Academy of Dermatology.

[27]  D. Nonaka,et al.  Sarcoma-like Tumor of Head and Neck Skin , 2014, The American journal of surgical pathology.

[28]  D. Schadendorf,et al.  TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas , 2014, Modern Pathology.

[29]  J. Hornick,et al.  Atypical fibroxanthoma with pseudoangiomatous features: a histological and immunohistochemical mimic of cutaneous angiosarcoma. , 2013, Annals of diagnostic pathology.

[30]  R. West,et al.  Reconsidering the Diagnostic and Prognostic Utility of LN-2 for Undifferentiated Pleomorphic Sarcoma and Atypical Fibroxanthoma , 2013, American journal of dermatopathology.

[31]  T. Brenn,et al.  Pleomorphic Dermal Sarcoma: Adverse Histologic Features Predict Aggressive Behavior and Allow Distinction From Atypical Fibroxanthoma , 2012, The American journal of surgical pathology.

[32]  T. McCalmont.  Correction and clarification regarding AFX and pleomorphic dermal sarcoma , 2012, Journal of cutaneous pathology.

[33]  T. McCalmont.  AFX: What We Now Know , 2011, Journal of cutaneous pathology.

[34]  P. Hartel,et al.  CD99 immunoreactivity in atypical fibroxanthoma and pleomorphic malignant fibrous histiocytoma: a useful diagnostic marker , 2006, Journal of cutaneous pathology.

[35]  H. Breuninger,et al.  Sentinel-Node-Biopsie , 2005, Der Hautarzt.